The most compelling evidence against this hypothesis is that large-scale population sequencing (such as gnomAD) and clinical sequencing show that people with C9orf72 heterozygous loss-of-function mutations do not develop C9-FTD/ALS (22). This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.